CR20190350A - INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS - Google Patents

INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS

Info

Publication number
CR20190350A
CR20190350A CR20190350A CR20190350A CR20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A CR 20190350 A CR20190350 A CR 20190350A
Authority
CR
Costa Rica
Prior art keywords
tgfß1
permissive
isoform
inhibitors
context
Prior art date
Application number
CR20190350A
Other languages
English (en)
Inventor
Constance Martin
Thomas Schurpf
Ashish Kalra
Kimberly Long
Alan Buckler
Gregory J Carven
Abhishek Datta
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of CR20190350A publication Critical patent/CR20190350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)

Abstract

En el presente documento se describe el uso terapéutico de inhibidores de TGFß1 isoforma-específicos, contexto-permisivos, en el tratamiento de enfermedades que implican la desregulación de TGFß1.
CR20190350A 2017-01-06 2018-01-05 INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS CR20190350A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201762443615P 2017-01-06 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US201762514417P 2017-06-02 2017-06-02
US201762529616P 2017-07-07 2017-07-07
US201762549767P 2017-08-24 2017-08-24
US201762558311P 2017-09-13 2017-09-13
US201762585227P 2017-11-13 2017-11-13
US201762587964P 2017-11-17 2017-11-17
US201762588626P 2017-11-20 2017-11-20
PCT/US2018/012601 WO2018129329A1 (en) 2017-01-06 2018-01-05 ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
CR20190350A true CR20190350A (es) 2019-11-15

Family

ID=61198888

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190350A CR20190350A (es) 2017-01-06 2018-01-05 INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS

Country Status (17)

Country Link
US (3) US20180207267A1 (es)
EP (1) EP3551658A1 (es)
JP (2) JP7157744B2 (es)
KR (1) KR20190098255A (es)
CN (2) CN117398457A (es)
AU (1) AU2018205231A1 (es)
BR (1) BR112019013908A2 (es)
CA (1) CA3049005A1 (es)
CL (1) CL2019001874A1 (es)
CO (1) CO2019007298A2 (es)
CR (1) CR20190350A (es)
DO (1) DOP2019000180A (es)
IL (2) IL267790A (es)
MX (1) MX2019008197A (es)
PE (1) PE20191661A1 (es)
PH (1) PH12019501575A1 (es)
WO (1) WO2018129329A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
WO2019023661A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
CA3105988A1 (en) 2018-07-11 2020-01-16 Abhishek Datta High-affinity, isoform-selective tgf.beta.1 inhibitors and use thereof
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CN113906298A (zh) * 2019-03-27 2022-01-07 新加坡保健服务集团有限公司 对腹膜癌扩散具有治疗意义的生物标志物
WO2020206055A1 (en) * 2019-04-02 2020-10-08 Yale University Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
TW202142571A (zh) 2019-08-28 2021-11-16 日商中外製藥股份有限公司 跨物種抗潛伏性TGF-β1抗體及使用方法
KR20220101137A (ko) 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CA3177030A1 (en) 2020-04-27 2021-11-04 Aaron Sato Variant nucleic acid libraries for coronavirus
IL298082A (en) 2020-06-03 2023-01-01 Gilead Sciences Inc lpa receptor antagonists and uses thereof
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN114957476A (zh) * 2021-02-23 2022-08-30 复旦大学 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AU2022273631A1 (en) 2021-05-11 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AU2022273702A1 (en) 2021-05-13 2023-11-02 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
KR102628959B1 (ko) 2022-03-22 2024-01-24 오토텔릭바이오 주식회사 티아졸 유도체 화합물 및 이의 용도
CN117721079A (zh) * 2024-01-26 2024-03-19 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CN101525384A (zh) 2000-06-29 2009-09-09 艾博特公司 双特异性抗体及其制备方法和用途
GB0230202D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Ligand
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2930677A1 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
BRPI0809042B1 (pt) * 2007-03-22 2021-08-31 Biogen Ma Inc. Proteína de ligação a cd154 isolada, seu uso, e composição
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
EP2672997A4 (en) * 2011-02-08 2015-05-06 Abbvie Inc TREATMENT OF ARTHROSIS AND PAIN
KR102577578B1 (ko) * 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
BR112014011115A2 (pt) * 2011-11-08 2017-06-13 Pfizer métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
DK2822592T3 (en) * 2012-03-08 2018-10-15 Ludwig Institute For Cancer Res Limited TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF
JP2016521283A (ja) * 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
EP3139957A4 (en) * 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof

Also Published As

Publication number Publication date
BR112019013908A2 (pt) 2020-02-04
CL2019001874A1 (es) 2019-12-06
MX2019008197A (es) 2019-09-11
US20180207267A1 (en) 2018-07-26
KR20190098255A (ko) 2019-08-21
DOP2019000180A (es) 2019-09-15
PE20191661A1 (es) 2019-11-11
CO2019007298A2 (es) 2019-07-31
EP3551658A1 (en) 2019-10-16
US20190209682A1 (en) 2019-07-11
IL267790A (en) 2019-09-26
CN110382530A (zh) 2019-10-25
AU2018205231A1 (en) 2019-07-18
JP2022188226A (ja) 2022-12-20
WO2018129329A1 (en) 2018-07-12
CN117398457A (zh) 2024-01-16
PH12019501575A1 (en) 2019-11-04
JP2020503362A (ja) 2020-01-30
IL304416A (en) 2023-09-01
US20240016928A1 (en) 2024-01-18
CA3049005A1 (en) 2018-07-12
JP7157744B2 (ja) 2022-10-20

Similar Documents

Publication Publication Date Title
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2018002698A1 (es) Tratamiento de enfermedades inflamatorias con inhibidores de actividad c5a
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2016002971A1 (es) Combinación.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20180260A1 (es) Metodos y kits para tratar la depresion
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CO2022000270A2 (es) Inhibidores de enzimas
UY38352A (es) Inhibidores de integrina alfavbeta6
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
BR112018071586A2 (pt) uso de beta-agonistas da tireoide